NASDAQ:BGLC BioNexus Gene Lab (BGLC) Stock Price, News & Analysis $0.29 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About BioNexus Gene Lab Stock (NASDAQ:BGLC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioNexus Gene Lab alerts:Sign Up Key Stats Today's Range$0.29▼$0.3150-Day Range$0.29▼$0.4552-Week Range$0.28▼$3.39Volume100,989 shsAverage Volume81,787 shsMarket Capitalization$5.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Read More… New post-election stock warning from Wall Street (Ad)If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...Not everything is as rosy as it seems on Wall Street. Receive BGLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address BGLC Stock News HeadlinesBioNexus Gene Lab Faces Delisting and Leadership ChangesNovember 9, 2024 | markets.businessinsider.comBioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.September 25, 2024 | globenewswire.comFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.November 24, 2024 | Porter & Company (Ad)BioNexus partners with Vitarray for gene detectionSeptember 16, 2024 | investing.comEuropean Central Bank cuts key interest rates as inflation fallsSeptember 15, 2024 | ca.finance.yahoo.comBioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.September 13, 2024 | globenewswire.comBioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare SolutionsSeptember 12, 2024 | globenewswire.comBioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste ProductionSeptember 11, 2024 | globenewswire.comSee More Headlines BGLC Stock Analysis - Frequently Asked Questions How have BGLC shares performed this year? BioNexus Gene Lab's stock was trading at $0.53 at the beginning of 2024. Since then, BGLC stock has decreased by 45.1% and is now trading at $0.2912. View the best growth stocks for 2024 here. When did BioNexus Gene Lab IPO? BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering (IPO) on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO. How do I buy shares of BioNexus Gene Lab? Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNexus Gene Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:BGLC CUSIPN/A CIK1737523 Webwww.bionexusgenelab.com Phone60-1-2212-6512FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,630,000.00 Net Margins-10.17% Pretax Margin-9.93% Return on Equity-9.93% Return on Assets-8.43% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.87 Sales & Book Value Annual Sales$9.77 million Price / Sales0.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book0.56Miscellaneous Outstanding Shares17,970,000Free Float17,605,000Market Cap$5.23 million OptionableNot Optionable Beta7.71 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BGLC) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.